Blood Collection in Patients with Fragile Veins Improved
|
By LabMedica International staff writers Posted on 08 Mar 2010 |

Image: The Microtainer MAP Microtube for Automated Process for hematology testing (photo courtesy BD Diagnostics).
A new hematology-testing device is designed to improve the safety, accuracy, and turnaround time of capillary blood collection and testing in patients with veins that can be difficult to access, such as infants, children, oncology patients, and the elderly.
BD Diagnostics (Franklin Lakes, NJ, USA), a segment of BD (Becton, Dickinson and Company), announced the launch of BD Microtainer MAP Microtube for Automated Process for hematology testing. The new BD Microtainer MAP product is also the first microtube to be fully compatible with most automated hematology instruments, reducing turnaround time, and costs associated with sample transfer and relabeling.
"Clinical laboratories are focused on preventing specimen identification errors that can lead to misdiagnosis of patients. We at BD are pleased to introduce the BD Microtainer MAP product to address this healthcare issue,” said Tom Polen, president, BD Diagnostics--Preanalytical Systems. "BD is committed to continuing our history of innovation in helping improve patient safety and healthcare worker safety, while enhancing workflow efficiency.”
The BD Microtainer MAP tube is the first low-volume collection system to accommodate standard, full-size patient identification labels, thus reducing the risk of labeling errors. This feature offers a significant improvement over traditional microcollection tubes, which are incompatible with standard labels due to their size. This disparity can lead to dangerous labeling errors that may result in misdiagnosis and incorrect patient treatment.
The preanalytic phase is a critical step in the diagnostic process, with significant impact to patient health, healthcare worker safety, and workflow efficiencies. Historically, low-volume capillary blood collection has increased test result turnaround time due to incompatibility with automated testing instruments and a higher risk of patient identification errors.
The innovative design of the BD Microtainer MAP tube enables automated processing with 81% less blood than venous systems, improving test turnaround time and laboratory efficiency. This is a critical improvement for patients from whom it is difficult to obtain a sufficient blood sample to perform critical diagnostic tests.
BD is a leading global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines.
Related Links:
BD Diagnostics
BD Diagnostics (Franklin Lakes, NJ, USA), a segment of BD (Becton, Dickinson and Company), announced the launch of BD Microtainer MAP Microtube for Automated Process for hematology testing. The new BD Microtainer MAP product is also the first microtube to be fully compatible with most automated hematology instruments, reducing turnaround time, and costs associated with sample transfer and relabeling.
"Clinical laboratories are focused on preventing specimen identification errors that can lead to misdiagnosis of patients. We at BD are pleased to introduce the BD Microtainer MAP product to address this healthcare issue,” said Tom Polen, president, BD Diagnostics--Preanalytical Systems. "BD is committed to continuing our history of innovation in helping improve patient safety and healthcare worker safety, while enhancing workflow efficiency.”
The BD Microtainer MAP tube is the first low-volume collection system to accommodate standard, full-size patient identification labels, thus reducing the risk of labeling errors. This feature offers a significant improvement over traditional microcollection tubes, which are incompatible with standard labels due to their size. This disparity can lead to dangerous labeling errors that may result in misdiagnosis and incorrect patient treatment.
The preanalytic phase is a critical step in the diagnostic process, with significant impact to patient health, healthcare worker safety, and workflow efficiencies. Historically, low-volume capillary blood collection has increased test result turnaround time due to incompatibility with automated testing instruments and a higher risk of patient identification errors.
The innovative design of the BD Microtainer MAP tube enables automated processing with 81% less blood than venous systems, improving test turnaround time and laboratory efficiency. This is a critical improvement for patients from whom it is difficult to obtain a sufficient blood sample to perform critical diagnostic tests.
BD is a leading global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines.
Related Links:
BD Diagnostics
Latest Clinical Chem. News
- Saliva-Based Test Detects Biochemical Signs of Sleep Loss
- Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
- Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
- Urine-Based Test Shows Promise for Autism Screening in Children
- Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s
- Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
- Urine-Based Alzheimer’s Test Receives FDA Breakthrough Device Designation
- Fluid Biomarker Improves Diagnosis and Monitoring of Primary CNS Lymphoma
- New CA19-9 Cutoff Value Helps Identify High-Risk Pancreatic Cancer Patients
- Blood-Based Biomarkers Show Promise for Psychosis Risk Prediction
- International Experts Recommend Ending Routine 'Corrected' Calcium Reporting
- Long-Term Data Show PSA Screening Modestly Reduces Prostate Cancer Deaths
- Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively
- FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing
- CE-Marked Blood Biomarker Test Advances Automated Alzheimer’s Diagnostics
- Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
Channels
Molecular Diagnostics
view channel
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read more
Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more








